Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Stressgen (VSE: SSB) -- Ignore unavailable to you. Want to Upgrade?

To: David Culver who wrote (144)	11/7/2000 6:30:33 PM
From: Heat Shock	Read Replies (1) \| Respond to of 236

David, as to potential revenue for this product, I saw a post on stockhouse.ca StressGen thread, stockhouse.ca which had an interesting rough estimate done in a nice analytical way. You'll have to search through the posts. It was in the last 2 months, I think. William, your 28 month estimate to Phase III is possible and with fast track approval, orphan drug status and whatever else could speed it along, it might be even less. Could easily be longer of course. Heat.